- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.03. | Ipsen to withdraw cancer drug acquired in buyout due to safety concerns | ||
| 09.03. | Novo, Hims reach deal to sell GLP-1 drugs together | ||
| 09.03. | Navigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies | ||
| 09.03. | Rethinking the box: Why circular cold chain packaging is becoming a cost strategy in healthcare | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | ||
| 06.03. | Roche, Zealand Pharma shares fall on 'undifferentiated' obesity drug results | ||
| 06.03. | FDA issues speedy approval to J&J's Tecvayli-Darzalex combo | ||
| 06.03. | Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs | ||
| 05.03. | Lilly targets employers in new bid to broaden access to obesity drugs | ||
| 05.03. | PepGen muscular dystrophy drug gets 'surprise' hold from FDA | ||
| 05.03. | A startup making drugs for blood disorders banks $160M | ||
| 04.03. | Moderna to pay up to $2.25B to end mRNA vaccine patent fight | ||
| 04.03. | Blackstone puts $400M into Teva, Sanofi gut disease drug | ||
| 04.03. | Prime to test FDA flexibility with 2-patient gene editing submission | ||
| 04.03. | FDA again targets GLP-1 compounders; Intellia to restart heart disease trial | ||
| 03.03. | Kyowa Kirin abandons touted eczema drug following safety review | ||
| 03.03. | Pierre Fabre seeks to revive US approval chances for spurned cell therapy | ||
| 02.03. | Candid Therapeutics, in a reverse merger with RallyBio, to go public | ||
| 02.03. | Ascendis wins FDA approval of dwarfism drug | ||
| 02.03. | UniQure says FDA wants another study of Huntington's gene therapy | ||
| 02.03. | Roche pill succeeds in another MS study, but approval questions linger | ||
| 02.03. | Safety concerns spur Aardvark to halt key Prader-Willi drug trial | ||
| 02.03. | Why it's critical to close open steps in cell therapy manufacturing | ||
| 27.02. | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | ||
| 27.02. | UniQure falls further on Makary comments |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.